secwatch.observer — SEC 8-K summary
======================================

Issuer:     Panbela Therapeutics, Inc. (—)
CIK:        0001029125
Form:       8-K
Filed at:   2023-12-01T23:59:59+00:00
Accession:  0001437749-23-033411
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Panbela receives Nasdaq delisting notice for bid price non-compliance; appeals hearing planned
--------------------------------------------------------------------------------

- Nasdaq notified Panbela on Nov 28, 2023 of bid price <$1 for 30 consecutive days; no grace period due to cumulative reverse splits >250:1.
- Trading suspension scheduled Dec 7, 2023, but company will appeal to Nasdaq Hearings Panel by Dec 5 to stay delisting.
- Also not compliant with minimum stockholders' equity of $2.5M; reported deficit of $2.483M as of Sep 30, 2023.
- Company intends to request hearing and may seek stockholder approval for another reverse split to regain compliance.
- No assurance that Panel will grant continued listing; stock remains listed pending hearing decision.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1029125/000143774923033411/0001437749-23-033411-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1029125/000143774923033411/pbla20231201_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-033411

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer